Recent studies show α-eleostearic acid and its methyl ester induce ferroptosis in senescent cells, reducing inflammation and improving muscle function in aged mice without toxicity, with clinical tri...
Senolytic and senomorphic therapies, including Rubedo’s RLS-1496 in Phase 1 trials, target senescent cells to treat aging diseases, boosted by AI-driven discovery and rising investment. New seno...
Senolytic and senomorphic therapies are advancing with compounds like RLS-1496 and α-ESA-me targeting senescent cells. Experts highlight challenges in biomarkers and safety, pushing for personalized ...
Zhang et al. (2026) discovered that α-eleostearic acid and its methyl ester act as novel senolytic agents by inducing ferroptosis in senescent cells, achieving over 80% clearance with minimal toxicit...
